


Annals of oncology : official journal of the
v. 24, no. 10 (Oct. 2013)
General Collection
W1 AN617D
2013-11-12 06:34:15

OXFORD
UNIVERSITY PRESS

ISSN 0923-7534 (print)
ISSN 1569-8041 (online)



Volume 24 No. 10 October 2013

Annals of Oncology

luc

PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE
NATIONAL INSTITUTES OF HEALTH

www.annonc.oxfordjournals.org

www.esmo.org

040571	ANNALS OF ONCOLOGY - ENGLISH EDITION
07917059	2013 VOLUME 24 ISSUE 10
	SISAC
	
	9895283



Scan to view this journal
on your mobile device



Genome & Co. v. Univ. of Chicago
PGR2019-00002
UNIV. CHICAGO EX. 2063

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

editorials

Information to women invited to mammography screening
S. H. Njor & M. von Euler-Chelpin 2467

Cancer patients and survivors: changing words or changing culture?
A. Surbone, M. A. Annunziata, A. Santoro, U. Tirelli & P. Tralongo 2468

Equipoise abandoned? Randomization and clinical trials
R. Kurzrock & D. J. Stewart 2471

reviews

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
G. H. Lyman, D. C. Dale, E. Culakova, M. S. Poniewierski, D. A. Wolff, N. M. Kuderer, M. Huang & J. Crawford 2475

Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
V. Heinemann, M. Haas & S. Boeck 2484

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
W. J. Gradishar 2492

original articles

breast cancer

Likelihood of early detection of breast cancer in relation to false-positive risk in life-time mammographic screening: population-based cohort study
J. D. M. Otten, J. Fracheboud, G. J. den Heeten, S. J. Otto, R. Holland, H. J. de Koning, M. J. M. Broeders & A. L. M. Verbeek 2501

Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients
S. Jiralerspong, E. S. Kim, W. Dong, L. Feng, G. N. Hortobagyi & S. H. Giordano 2506

Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients
A. Giordano, H. Gao, E. N. Cohen, S. Anfossi, J. Houry, K. Hess, S. Krishnamurthy, S. Tim, M. Cristofanilli, G. N. Hortobagyi, W. A. Woodward, A. Lucci & J. M. Reuben 2515

Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy

J. Sohn, K. A. Do, S. Liu, H. Chen, G. B. Mills, G. N. Hortobagyi, F. Meric-Bernstam & A. M. Gonzalez-Angulo 2522

A comparison of hormonal profiles between breast cancer and benign breast disease: a case-control study
P. Lagiou, E. Samoli, A. Lagiou, P. Zourna, A. Barbouni, C. Georgila, A. Tsikkini, D. Vassilarou, P. Minaki, C. Sfikas, E. Spanos & D. Trichopoulos 2527

Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer

J. Q. Chen, Y. Bao, J. Lee, J. L. Murray, J. K. Litton, L. Xiao, R. Zhou, Y. Wu, X. Y. Shen, H. Zhang, A. A. Sahin, R. L. Katz, M. L. Bondy, N. L. Berinstein, G. N. Hortobagyi & L. G. Radvanyi 2534

Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
W. Jonat, T. Bachelot, T. Ruhstaller, I. Kuss, U. Reimann & J. F. R. Robertson 2543

N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial
W. W. Tan, A. C. Dueck, P. Flynn, P. Steen, D. Anderson, K. Rowland, D. Northfelt & E. A. Perez 2548

gastrointestinal tumors

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
M. K. Boisen, J. S. Johansen, C. Dehlendorff, J. S. Larsen, K. Østerlind, J. Hansen, S. E. Nielsen, P. Pfeiffer, L. S. Tarpgaard, N. H. Holländer, N. Keldsen, T. F. Hansen, B. B. Jensen & B. V. Jensen 2554

Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912

Y. Yamada, N. Boku, T. Nishina, K. Yamaguchi, T. Denda, A. Tsuji, Y. Hamamoto, K. Konishi, Y. Tsuji, K. Amagai, S. Ohkawa, Y. Fujita, H. Nishisaki, H. Kawai, A. Takashima, J. Mizusawa, K. Nakamura & A. Ohtsu 2560

Continued overleaf

A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
L. Kadalayil, R. Benini, L. Pallan, J. O'Beirne, L. Marelli, D. Yu, A. Hackshaw, R. Fox, P. Johnson, A. K. Burroughs, D. H. Palmer & T. Meyer **2565**

TNF- α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy
M. Roselli, P. Ferroni, C. Rolfo, M. Peeters, R. Palmirotta, V. Formica, G. Ludovici, A. Laudisi, M. L. De Marchis, F. La Farina, A. Russo & F. Guadagni **2571**

Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)
H. Fensterer, C. Schade-Brittinger, H. -H. Müller, S. Tebbe, J. Fass, U. Lindig, U. Settmacher, W. E. Schmidt, A. Märten, M. P. Ebert, M. Kornmann, R. Hofheinz, E. Endlicher, C. Brendel, P. J. Barth, D. K. Bartsch, P. Michl & T. M. Gress for the Arbeitsgemeinschaft Internistische Onkologie (AIO) **2576**

Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
L. Stenholm, J. Stoehlmacher-Williams, S. E. Al-Batran, N. Heussen, S. Akin, C. Pauligk, S. Lehmann, T. Senff, R. D. Hofheinz, G. Ehninger, M. Kramer & E. Goekkurt **2581**

lung cancer

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
J. Ying, L. Guo, T. Qiu, L. Shan, Y. Ling, X. Liu & N. Lu **2589**

Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification
R. Noro, K. Honda, K. Tsuta, G. Ishii, A. M. Maeshima, N. Miura, K. Furuta, T. Shibata, H. Tsuda, A. Ochiai, T. Sakuma, N. Nishijima, A. Gemma, H. Asamura, K. Nagai & T. Yamada **2594**

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
R. J. Kelly, A. Thomas, A. Rajan, G. Chun, A. Lopez-Chavez, E. Szabo, S. Spencer, C. A. Carter, U. Guha, S. Khozin, S. Poondru, C. Van Sant, A. Keating, S. M. Steinberg, W. Figg & G. Giaccone **2601**

Red meat, Mediterranean diet and lung cancer risk among heavy smokers in the COSMOS screening study
P. Gnagnarella, P. Maisonneuve, M. Bellomi, C. Rampinelli, R. Bertolotti, L. Spaggiari, D. Palli & G. Veronesi **2606**

hematologic malignancies

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA
A. Trebouet, T. Marchand, R. Lemal, E. Gyan, F. Broussais-Guillaumot, Y. Guillermin, H. Monjanel, G. Salles, S. Le Gouill, P. Godmer, C. Fruchart, G. Damaj, P. Feugier, C. Thieblemont, M. Maynadié, A. Monnereau, X. Troussard, D. Rossille, T. Lamy & R. Houot **2612**

Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma
R. Herbrecht, P. Cernohous, A. Engert, S. Le Gouill, D. Macdonald, C. Machida, H. Myint, A. Saleh, J. Singer, M. Wilhelm & R. van der Jagt **2618**

head and neck cancer

Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours
J. Cros, E. Sbidian, S. Hans, H. Roussel, F. Scotte, E. Tartour, D. Brasnu, P. Laurent-Puig, P. Bruneval, H. Blons & C. Badoual **2624**

quality of life and supportive care

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer
J. Cortés, J. Baselga, Y.-H. Im, S.-A. Im, X. Pivot, G. Ross, E. Clark, A. Knott & S. M. Swain **2630**

Informal caregiving to older cancer patients: preliminary research outcomes and implications
G. Goldzweig, S. Merims, R. Ganon, T. Peretz, A. Altman & L. Baider **2635**

oncology practice

Attitude of employees of a university clinic to complementary and alternative medicine in oncology
A. Trimborn, B. Senf, K. Muenstedt, J. Buentzel, O. Micke, R. Muecke, F. J. Prott, S. Wicker & J. Huebner, on behalf of Working group Prevention and Integrative Oncology (PRIO) of the German Cancer Society **2641**

Continued overleaf

epidemiology

Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort

M. Obón-Santacana, N. Slimani, L. Lujan-Barroso, N. Travier, G. Hallmans, H. Freisling, P. Ferrari, M. C. Boutron-Ruault, A. Racine, F. Clavel, C. Saieva, V. Pala, R. Tumino, A. Mattiello, P. Vineis, M. Argüelles, E. Ardanaz, P. Amiano, C. Navarro, M. J. Sánchez, E. Molina Montes, T. Key, K.-T. Khaw, N. Wareham, P. H. Peeters, A. Trichopoulou, C. Bamia, D. Trichopoulos, H. Boeing, R. Kaaks, V. Katzke, W. Ye, M. Sund, U. Ericson, E. Wirfält, K. Overvad, A. Tjønneland, A. Olsen, G. Skeie, L. A. Åsli, E. Weiderpass, E. Riboli, H. B. Bueno-de-Mesquita & E. J. Duell **2645**

Family history of cancer and the risk of cancer: a network of case-control studies

F. Turati, V. Edefonti, C. Bosetti, M. Ferraroni, M. Malvezzi, S. Franceschi, R. Talamini, M. Montella, F. Levi, L. Dal Maso, D. Serraino, J. Polesel, E. Negri, A. Decarli & C. La Vecchia **2651**

Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980

C. Bosetti, P. Bertuccio, M. Malvezzi, F. Levi, L. Chatenoud, E. Negri & C. La Vecchia **2657**

sarcomas and melanoma

Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998)

R. B. Keus, R. A. Nout, J.-Y. Blay, J. M. de Jong, I. Hennig, F. Saran, J. T. Hartmann, M. P. Sunyach, S. J. Gwyther, M. Ouali, A. Kirkpatrick, P. M. Poortmans, P. C. W. Hogendoorn & W. T. A. van der Graaf **2672**

Limb preservation surgery with extracorporeal irradiation in the management of malignant bone tumor: the oncological outcomes of 101 patients

A. M. Hong, S. Millington, V. Ahern, G. McCowage, R. Boyle, M. Tattersall, L. Haydu & P. D. Stalley **2676**

Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group

S. Cousin, J. Y. Blay, F. Bertucci, N. Isambert, A. Italiano, E. Bompas, I. Ray-Coquard, D. Perrot, M. Chaix, B. Bui-Nguyen, L. Chaigneau, N. Corradini & N. Penel **2681**

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

S. Wilgenhof, A. M. T. Van Nuffel, D. Benteyn, J. Corthals, C. Aerts, C. Heirman, I. Van Riet, A. Bonehill, K. Thielemans & B. Neyns **2686**

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)

D. McDermott, J. Haanen, T.-T. Chen, P. Lorigan & S. O'Day for the MDX010-20 investigators **2694**

cancer prevention

Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study

T. Tabuchi, Y. Ito, A. Ioka, T. Nakayama, I. Miyashiro & H. Tsukuma **2699**

letter to the editor

Detection of aberrant methylation of 10 genes in genomic DNA of lung tumors

R. Sheikhejad, M. Zohri, M. B. Shadmehr, M. Rahmani-Khalili, N. Doozande, Z. Farsad & K. Sheikhzade **2705**

corrigenda

Needs regarding care and factors associated with unmet needs in disease-free survivors of surgically treated lung cancer

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer **2708**

subscriptions

A subscription to *Annals of Oncology* comprises 12 issues plus supplements in each volume. Prices include postage, and for subscribers outside the UK delivery is by Standard Air.

Annual Subscription Rate (Volume 24, 12 issues, 2013)

Institutional – Academic / Non profit only
Print and Online £1319.00/\$2639.00/€1980.00
Online Only £1044.00/\$2089.00/€1568.00
Print Only £1209.00/\$2419.00/€1815.00

Institutional – Corporate
Print and Online £1649.00/\$3299.00/€2475.00
Online Only £1305.00/\$2611.00/€1959.00
Print Only £1511.00/\$3024.00/€2269.00

Personal
Print and Online £1144.00/\$2288.00/€1717.00
Please note: US\$ rate applies to US & Canada, Euros applies to Europe, UK£ applies to UK and Rest of World.

There may be other subscription rates available, for a complete listing please visit www.annonc.oxfordjournals.org/subscriptions

Full prepayment, in the correct currency, is required for all orders. Orders are regarded as firm and payments are not refundable. Subscriptions are accepted and entered on a complete volume basis. Claims cannot be considered more than FOUR months after publication or date of order, whichever is later. All subscriptions in Canada are subject to GST. Subscriptions in the EU may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Personal rate subscriptions are only available if payment is made by personal cheque or credit card and delivery is to a private address.

The current year and two previous years' issues are available from Oxford Journals. Previous volumes can be obtained from the Periodicals Service Company at <http://www.periodicals.com/oxford.html> or Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Email: psc@periodicals.com. Tel: (518) 537-4700. Fax: (518) 537-5899

For further information, please contact: Journals Customer Service Department, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Email: jnl.cust.serv@oup.com. Tel (and answerphone outside normal working hours): +44 (0)1865 353907. Fax: +44 (0)1865 353485. **In the US, please contact:** Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513, USA. Email: jnlorders@oup.com. Tel (and answerphone outside normal working hours): 800 852 7323 (toll-free in USA/Canada). Fax: 919 677 1714. **In Japan, please contact:** Journals Customer Service, Oxford University Press, 4-5-10-8F Shiba, Minato-ku, Tokyo 108-8386, Japan. Tel. +81 3 5444 5858. Fax. +81 3 3454 2929. E-mail: custserv.jp@oup.com

DOI: For information about DOIs and to resolve them, please visit <http://www.doi.org>

Methods of payment. (i) Cheque (payable to Oxford University Press, to Oxford University Press, Cashiers Office, Great Clarendon Street, Oxford OX2 6DP, UK) in GBE Sterling (drawn on a UK bank), US\$ Dollars (drawn on a US bank), or EU€ Euros. (ii) Bank transfer to Barclays Bank Plc, Oxford

Group Office, Oxford (bank sort code 20-65-18) (UK), overseas only Swift code BARC GB 22 (GBE Sterling to account no. 70299332, IBAN GB89BARC20651870299332; US\$ Dollars to account no. 66014600, IBAN GB27BARC20651866014600; EU€ Euros to account no. 78923655, IBAN GB16BARC20651878923655). (iii) Credit card (Mastercard, Visa, Switch or American Express).

Annals of Oncology (ISSN 0923-7534) is published monthly by Oxford University Press, Oxford, UK. The US annual print subscription or price is \$2513.00. Airfreight and mailing in the USA by agent named Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Jamaica NY 11431.

Subscription records are maintained at Oxford University Press, Oxford, UK.

supplements, reprints and corporate sales

For requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation opportunities for previously published material, and corporate online opportunities, please email: special.sales@oup.com, fax: +44 (0) 1865 353774 or visit www.oxfordjournals.org/sales.

permissions

For information on how to request permissions to reproduce articles/information from this journal, please visit www.oxfordjournals.org/permissions.

advertising

Advertising, inserts and artwork enquiries should be addressed to Advertising and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax +44 (0)1865 353774; E-mail: jnladvertising@oup.com

environmental and ethical policies

Oxford Journals, a division of Oxford University Press, is committed to working with the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementing environmentally friendly policies and practices wherever possible. Please see <http://www.oxfordjournals.org/ethicalpolicies.html> for further information on environmental and ethical policies.

drug disclaimer

All reasonable precautions have been taken by the authors, editors and publisher to verify drug names and doses, the results of experimental work and the clinical findings published in this journal. The opinions expressed are those of the authors, and not necessarily those of the editors or publisher. The ultimate responsibility for the use and dosage of drugs mentioned in *Annals of Oncology* and in the interpretation of published material lies with the medical practitioner. The editors and publisher can accept no liability whatsoever in respect of any claim for damages arising therefrom. Please inform the editors of any errors.

© The European Society for Medical Oncology 2013

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923.

Typeset by Techset Composition Ltd, Salisbury, UK.
Printed by Bell and Bain Ltd., Glasgow, UK.



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.